CD69 serves as a potential diagnostic and prognostic biomarker for hepatocellular carcinoma

Abstract

The prevalence and mortality of hepatocellular carcinoma (HCC) are still increasing. This study aimed to identify potential therapeutic targets related to patient prognosis. Data were downloaded from TCGA, GSE25097, GSE36376, and GSE76427 datasets. Differential analysis and enrichment analysis were performed in HCC. Cell deaths were evaluated, and least absolute shrinkage and selection operator regression (LASSO) regression was analyzed to screen candidate genes. Additionally, immune cell infiltration in HCC was assessed. We identified 4088 common DEGs with the same direction of differential expression in all four datasets, they were mainly enriched in immunoinflammation and cell cycle pathways. Apoptosis was significantly suppressed in HCC in GSEA and GSVA. After LASSO regression analysis, we screened CD69, CDC25B, MGMT, TOP2A, and TXNIP as candidate genes. Among them, CD69 significantly influenced the overall survival of HCC patients in both TCGA and GSE76427. CD69 may be a protective factor for outcome of HCC patients. In addition, CD69 was positive correlation with T cells and CD3E. CD69, CDC25B, MGMT, TOP2A, and TXNIP were potential diagnostic and prognostic target for HCC, especially CD69.

Zinc finger protein 296 promotes hepatocellular carcinoma progression via inducing interaction between macrophages and B cells

“…CD69 is signi cantly and positively correlated with T cells. The increased expression of CD69 may change the immunosuppressed tumor microenvironment into an immune state with a better prognosis, which may explain why HCC patients with high expression of CD69 had a better prognosis 21,22 . Besides, recent research has shown that BRI3 is identi ed as a new downstream target of the Wnt/ β-catenin signaling, which may be related to the poorer prognosis of HCC.…”